Coya Therapeutics Inc. (COYA), a clinical-stage biotechnology company, which is optimistic about the strategic opportunities that lie ahead, both with existing and new partners, looks forward to delivering shareholder value in 2025.
The company expects to present additional data from its Phase 2 investigator-initiated study of COYA 302, otherwise known as Low Dose Interleukin-2 (LD IL-2), in patients with mild-to-moderate Alzheimer's next quarter (Q1, 2025).
Subscribe to continue reading the article.
This article is part of our premium content offering.Subscribe with a RTTNews subscription.
Subscribe NowAlready subscribed? Sign in
For comments and feedback: editorial@rttnews.com